PHARMACOKINETICS OF DIDEOXYPURINE NUCLEOSIDE ANALOGS IN PLASMA AND CEREBROSPINAL-FLUID OF RHESUS-MONKEYS

被引:13
作者
HAWKINS, ME
MITSUYA, H
MCCULLY, CM
GODWIN, KS
MURAKAMI, K
POPLACK, DG
BALIS, FM
机构
[1] NCI,PEDIAT BRANCH,BETHESDA,MD 20892
[2] NCI,MED BRANCH,BETHESDA,MD 20892
[3] NIPPON PAPER IND CORP,IWAKUNI RES LAB TECHNOL,IWAKUNI,YAMAGUCHI,JAPAN
关键词
D O I
10.1128/AAC.39.6.1259
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics of 2',3'-dideoxyadenosine (ddA), didanosine, 2',3'-dideoxyguanosine (ddG), and 6-halogenated prodrugs of ddG, 6-chloro-ddG and 6-iodo-ddG, in plasma and cerebrospinal fluid (CSF) were studied in a non-human primate model, ddA was rapidly and completely deaminated to didanosine, such that didanosine concentration profiles in plasma and CSF were identical following administration of ddA and didanosine, The mean clearance of didanosine was 0.50 liters/h/kg, the terminal half-life was 1.8 h, and the CSF-to-plasma ratio was 4.8%, The disposition of ddG was similar, with a clearance of 0.70 liters/h/kg and a half-life of 1.7 h, The adenosine deaminase-mediated conversion of the 6-halogenated-ddG prodrugs to ddG was rapid but incomplete (48% for 6-chloro-ddG and 29% for 6-iodo-ddG), The CSF-to-plasma ratios of ddG with equimolar doses of ddG, 6-chloro-ddG, and 6-iodo-ddG were 8.5, 24, and 17%, respectively, but the actual ddG exposures in CSF (area under the CSF concentration-time curve) were comparable for ddG (12.1 mu M . h) and the 6-halogenated-ddG prodrugs (18.8 mu M . h for 6 chloro-ddG, 9.3 mu M . h for 6-iodo-ddG), 6-Chloro-ddG was not detectable in plasma or CSF, and the CSF-to-plasma ratio of 6-iodo-ddG was 9.4%, so the higher CSF-to-plasma ratios of ddG,vith the administration of the 6-halogenated-ddG prodrugs does not appear to be the result of enhanced penetration of the prodrug and subsequent dehalogenation to ddG, The penetration of ddG into CSF exceeds that of didanosine and is enhanced by administration of the 6-halogenated prodrugs, although the mechanism of this enhanced penetration is unclear.
引用
收藏
页码:1259 / 1264
页数:6
相关论文
共 23 条
  • [1] CLINICAL-PHARMACOLOGY OF 2',3'-DIDEOXYINOSINE IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
    BALIS, FM
    PIZZO, PA
    BUTLER, KM
    HAWKINS, ME
    BROUWERS, P
    HUSSON, RN
    JACOBSEN, F
    BLANEY, SM
    GRESS, J
    JAROSINSKI, P
    POPLACK, DG
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) : 99 - 104
  • [2] THE PHARMACOKINETICS OF ZIDOVUDINE ADMINISTERED BY CONTINUOUS INFUSION IN CHILDREN
    BALIS, FM
    PIZZO, PA
    MURPHY, RF
    EDDY, J
    JAROSINSKI, PF
    FALLOON, J
    BRODER, S
    POPLACK, DG
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 110 (04) : 279 - 285
  • [3] ANTIRETROVIRAL THERAPY IN AIDS
    BRODER, S
    MITSUYA, H
    YARCHOAN, R
    PAVLAKIS, GN
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 113 (08) : 604 - 618
  • [4] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR ANALYSIS OF 2',3'-DIDEOXYINOSINE IN HUMAN-BODY FLUIDS
    CARPEN, ME
    POPLACK, DG
    PIZZO, PA
    BALIS, FM
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 526 (01): : 69 - 75
  • [5] COLLINS JM, 1988, J PHARMACOL EXP THER, V245, P466
  • [6] DONEHOWER RC, 1986, CANCER TREAT REP, V70, P1059
  • [7] CENTRAL NERVOUS-SYSTEM INVOLVEMENT IN HIV INFECTION
    GALLO, P
    DEROSSI, A
    AMADORI, A
    TAVOLATO, B
    CHIECOBIANCHI, L
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1988, 4 (03) : 211 - 221
  • [8] Gibaldi M., 1982, PHARMACOKINETICS, P445
  • [9] PHARMACOKINETICS OF 2',3'-DIDEOXYADENOSINE AND 2',3'-DIDEOXYINOSINE IN PATIENTS WITH SEVERE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION
    HARTMAN, NR
    YARCHOAN, R
    PLUDA, JM
    THOMAS, RV
    MARCZYK, KS
    BRODER, S
    JOHNS, DG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) : 647 - 654
  • [10] HO DHW, 1980, CANCER TREAT REP, V64, P629